Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 10,000 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 10,000 shares of the stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $78.64, for a total transaction of $786,400.00. Following the completion of the transaction, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at approximately $55,733,662.16. The trade was a 1.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Helen Torley also recently made the following trade(s):

• On Tuesday, February 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $76.12, for a total value of $1,522,400.00.
• On Monday, December 1st, Helen Torley sold 16,569 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $68.92, for a total value of $1,141,935.48.
• On Tuesday, November 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.13, for a total value of $1,382,600.00.

Halozyme Therapeutics Trading Up 0.6%

Shares of NASDAQ HALO traded up $0.49 during trading hours on Thursday, hitting $78.42. 2,481,744 shares of the company traded hands, compared to its average volume of 1,709,236. The stock has a market capitalization of $9.22 billion, a price-to-earnings ratio of 16.51, a price-to-earnings-growth ratio of 0.32 and a beta of 0.97. The company has a current ratio of 1.59, a quick ratio of 1.37 and a debt-to-equity ratio of 1.59. The company’s 50 day moving average price is $69.23 and its 200 day moving average price is $68.91. Halozyme Therapeutics, Inc. has a 12 month low of $47.50 and a 12 month high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The company had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.Halozyme Therapeutics’s revenue was up 22.1% on a year-over-year basis. During the same period last year, the company earned $1.27 earnings per share. On average, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

More Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised a slate of quarterly and annual EPS estimates (notably Q1 2026 to $1.42 from $1.19, Q2 2026 to $1.80 from $1.49, Q3 2026 to $1.83 from $1.70, Q4 2026 to $2.38 from $1.84 and FY2026 to $7.43 from $6.22), signaling stronger expected profitability and supporting forward valuation. (summary of Zacks Research estimate updates)
• Positive Sentiment: An analyst raised Halozyme’s Q1 EPS forecast, which reinforces the near‑term beat narrative and likely contributed to buying interest. Q1 EPS Forecast for Halozyme Therapeutics Raised by Analyst
• Positive Sentiment: Zacks published a positive style/value write‑up describing HALO as a top long‑term value stock, which can attract value‑oriented and institutional buyers. Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
• Neutral Sentiment: Zacks trimmed its Q3 2027 estimate slightly (to $1.99 from $2.02); the change is minor relative to the larger upward revisions and unlikely to meaningfully reverse the positive sentiment unless further downgrades follow. (summary of Zacks Research estimate change)

Institutional Trading of Halozyme Therapeutics

Large investors have recently modified their holdings of the company. DLD Asset Management LP increased its holdings in Halozyme Therapeutics by 20.0% during the 3rd quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock worth $2,200,200,000 after purchasing an additional 5,000,000 shares during the period. Arrowstreet Capital Limited Partnership grew its position in shares of Halozyme Therapeutics by 29.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after buying an additional 749,484 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Halozyme Therapeutics by 3.2% during the third quarter. Dimensional Fund Advisors LP now owns 2,078,426 shares of the biopharmaceutical company’s stock valued at $152,431,000 after buying an additional 63,699 shares during the period. Federated Hermes Inc. raised its holdings in shares of Halozyme Therapeutics by 294.1% in the third quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock valued at $106,395,000 after acquiring an additional 1,082,638 shares in the last quarter. Finally, LSV Asset Management lifted its stake in Halozyme Therapeutics by 0.9% in the third quarter. LSV Asset Management now owns 1,266,027 shares of the biopharmaceutical company’s stock worth $92,850,000 after acquiring an additional 10,787 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on HALO. Citizens Jmp upped their price target on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a report on Tuesday, November 4th. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Tuesday, November 4th. Leerink Partners upgraded Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price objective for the company in a report on Tuesday, October 14th. Finally, Morgan Stanley cut their price objective on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research report on Monday, October 20th. Seven investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Hold” and an average target price of $78.80.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.